Financial Performance - The company's operating revenue for Q1 2024 was RMB 1,373,251,921.93, representing a 5.55% increase compared to RMB 1,301,021,684.04 in the same period last year[3]. - Net profit attributable to shareholders for Q1 2024 was RMB 155,040,262.39, a significant increase of 133.00% from RMB 66,540,023.25 in the previous year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 157,052,354.18, reflecting a 253.00% increase from RMB 44,491,211.83 year-on-year[3]. - Basic and diluted earnings per share for Q1 2024 were both RMB 0.1057, up 133.33% from RMB 0.0453 in the previous year[3]. - Operating profit for the reporting period reached RMB 196.85 million, a 167.28% increase compared to the same period last year, primarily due to increased gross profit and reduced expenses[9]. - The total profit for the current period is RMB 181,205,852.66, a significant increase of 133.3% compared to RMB 77,557,847.95 in the previous period[24]. - Net profit attributable to the parent company is RMB 155,040,262.39, up from RMB 66,540,023.25, representing a growth of 132.7%[24]. - The operating profit for the current period is RMB 196,847,737.66, compared to RMB 73,649,081.61 in the previous period, indicating an increase of 167.1%[24]. - The total comprehensive income for the current period is RMB 150,135,056.48, which is an increase of 142.3% from RMB 61,856,551.06 in the previous period[26]. Cash Flow - The net cash flow from operating activities reached RMB 880,453,882.15, a remarkable turnaround from a negative cash flow of RMB -213,979,198.80 in the same period last year, marking a 511.47% improvement[3]. - Cash inflow from operating activities is RMB 1,664,646,503.27, down from RMB 1,936,382,607.31, a decrease of 14%[27]. - Cash outflow from operating activities totals RMB 784,192,621.12, a decrease from RMB 2,150,361,806.11, indicating a reduction of 63.5%[28]. - Net cash flow from operating activities is RMB 880,453,882.15, a significant recovery from a negative cash flow of RMB -213,979,198.80 in the previous period[28]. - Cash inflow from investment activities is RMB 441,112,963.21, down from RMB 1,206,613,179.47, a decrease of 63.4%[28]. - Net cash flow from investment activities is RMB 130,688,287.99, a decrease of 83.6% compared to RMB 795,650,734.04 in the previous period[28]. - Cash inflow from financing activities totaled approximately ¥835.83 million, down from ¥1,604.26 million in the previous period, representing a decrease of about 47.9%[29]. - Cash outflow from financing activities amounted to approximately ¥1,506.67 million, compared to ¥1,723.83 million last period, indicating a decrease of about 12.6%[29]. - Net cash flow from financing activities was negative at approximately -¥670.83 million, worsening from -¥119.57 million in the previous period[29]. - The net increase in cash and cash equivalents for the period was approximately ¥342.74 million, down from ¥433.44 million in the previous period[29]. - The ending balance of cash and cash equivalents reached approximately ¥2,108.38 million, an increase from ¥1,753.15 million in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,874,970,670.54, a decrease of 1.71% from RMB 19,203,415,131.24 at the end of the previous year[3]. - Total liabilities decreased to RMB 6,736,457,897.24 from RMB 7,215,037,414.42, reflecting a reduction of about 6.6%[21]. - The company's total equity increased to RMB 12,138,512,773.30 from RMB 11,988,377,716.82, reflecting a growth of approximately 1.3%[22]. - Cash and cash equivalents at the end of the period were RMB 2,225,125,933.99, compared to RMB 1,851,642,224.58 at the beginning of the period, showing an increase of about 20.2%[18]. - Inventory decreased to RMB 6,341,627,515.17 from RMB 6,654,110,787.81, indicating a decline of approximately 4.7%[18]. - Long-term equity investments decreased to RMB 943,735,674.53 from RMB 1,004,045,899.43, a decrease of about 6.0%[19]. - Total operating costs decreased to RMB 1,184,463,117.86 from RMB 1,239,337,824.93, indicating a reduction of about 4.4%[23]. Research and Development - Research and development expenses for Q1 2024 were RMB 35,294,968.25, an increase of 33.11% compared to RMB 26,514,765.57 in the same period last year[8]. - Research and development expenses increased to RMB 35,294,968.25, up from RMB 26,514,765.57, representing a growth of approximately 33.2%[23]. Market Strategy - The company plans to accelerate its sales strategy in New Zealand and Thailand following the approval of its heparin sodium injection in these markets[11]. - The company is focusing on expanding its market share in the heparin sodium formulation business, ranking second in sales in Europe during the reporting period[12]. - The CDMO business has shown significant revenue growth compared to the previous year, driven by the integration of resources and expansion of customer base[13]. - The company aims to enhance its development momentum and fully leverage its competitive advantages to achieve breakthrough growth in 2024[14]. - The focus will be on expanding sales in key overseas markets, particularly in Europe and the United States, while also targeting new non-European and non-American markets[14]. - In the heparin industry chain, the company will continue to prioritize centralized procurement in the Chinese market to drive sales growth[14]. - The company plans to implement a dual-driven platform strategy in its CDMO segment to maximize project value for clients and improve the success rate of ongoing projects[14]. Shareholder Information - The company reported a total of 28,328 common shareholders at the end of the reporting period, with the top two shareholders holding 60.12% of the shares[15]. - Shenzhen Le Ren Technology Co., Ltd. holds 32.31% of the shares, while Xiamen Jintian Soil Investment Partnership holds 27.81%[15]. Financial Incidents - The company experienced a telecom fraud incident involving approximately €11.7 million, with an impact of RMB 15.56 million on pre-tax profit and net profit for 2024[17]. - The actual controller of the company provided an advance payment of RMB 89.81 million to safeguard the interests of the company and its investors[17]. Financial Management - The company is actively managing its financial structure and cost control to balance financial risks and reduce capital costs[11]. - The company will continue to adopt prudent financial and liquidity management to enhance management efficiency and risk control[14]. - The company is committed to maximizing asset value and improving profitability through resource integration and strategic investments[14].

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 5,431.0 million, a decrease of 24.1% compared to RMB 7,151.0 million in 2022[2] - The company's loss attributable to equity holders for 2023 was RMB 783.3 million, compared to a profit of RMB 727.4 million in 2022[2] - The company reported a net loss of RMB 802.2 million for the year, compared to a profit of RMB 715.0 million in 2022[4] - The adjusted profit attributable to equity holders, excluding investment losses and inventory impairment, was RMB 387.0 million, down from RMB 841.9 million in 2022[10] - The total revenue for the year 2023 decreased by 24.1% to RMB 5,430.97 million, compared to RMB 7,151.04 million in 2022[23] - The company reported a pre-tax loss of RMB 928,334,000 for the year, influenced by various expenses including financing costs of RMB 228,087,000[50] Revenue Breakdown - The sales revenue from the formulation business was RMB 2,979.0 million, a decline from RMB 3,210.5 million in 2022[2] - The sales revenue from the API business was RMB 1,307.3 million, down from RMB 2,673.8 million in 2022[2] - The CDMO business generated sales revenue of RMB 967.0 million, compared to RMB 1,084.1 million in 2022[2] - The heparin industry chain business generated sales revenue of RMB 4,286.3 million, compared to RMB 5,884.3 million in 2022[12] - The formulation sales maintained stability with revenue of RMB 2,979.0 million, accounting for 54.9% of total revenue, and a gross profit margin increase to 43.1% from 35.3% in 2022[12] - Revenue from the pharmaceutical segment was RMB 2,979,030,000, while API segment revenue was RMB 1,307,343,000, and CDMO services generated RMB 966,952,000[57] Asset and Liability Management - Total non-current assets as of December 31, 2023, amounted to RMB 8,599.1 million, an increase from RMB 8,343.7 million in 2022[6] - Total current assets decreased to RMB 10,604.3 million from RMB 12,472.3 million in 2022[6] - Total current liabilities were RMB 4,986.2 million, down from RMB 5,575.8 million in 2022[6] - The company's net asset value stood at RMB 11,988,377 thousand, a reduction from RMB 12,409,465 thousand in 2022, reflecting a decline of approximately 3.4%[7] - Total assets were approximately RMB 19,203.4 million, with total liabilities of approximately 7,215.0 million, resulting in a debt-to-asset ratio of about 37.6%[36] Market Conditions and Challenges - In 2023, the global heparin market faced significant challenges, with the average export price of heparin dropping to USD 4,805 per kg by October, down from USD 11,779 per kg in July, marking a decline of about 59%[9] - The overall economic environment in 2023 was characterized by high inflation and tightening monetary policies, with global trade expected to decrease by 5% compared to the previous year[8] - China's GDP growth for 2023 was recorded at 5.2%, with quarterly growth rates of 4.5%, 6.3%, 4.9%, and 5.2% respectively[8] Impairments and Losses - The company recorded an inventory impairment provision of RMB 855.4 million due to the significant drop in heparin prices and demand fluctuations[9] - The company recognized goodwill impairment loss of RMB 68.2 million, primarily due to difficulties in the CDMO asset group and a decrease in innovative drug orders[29] - Impairment loss on property, plant, and equipment, and other intangible assets amounted to RMB 44.5 million, related to the AR-301 injection development project[30] - The total impairment loss recognized in the income statement was RMB 61,067,000, with the highest losses in the API segment[53] Strategic Initiatives and Future Plans - The company aims to expand its heparin product sales scale as a primary task for 2024, focusing on enhancing market share and operational efficiency[22] - The company plans to optimize resource allocation in its CDMO business to meet diverse customer project needs and enhance production capacity[21] - The company is actively expanding its international market presence and enhancing its sales network in the U.S. and Europe to seek new growth opportunities[10] - The company plans to continue exploring collaboration opportunities and accelerate the strategic layout of innovative drugs through partnerships[10] - The company will strengthen its market presence in the U.S. by collaborating with strategic partners and leveraging its own sales team[21] Clinical Trials and Product Development - Oregovomab's Phase III clinical trial did not meet its primary endpoint, but data suggests potential benefits for patients over 65 and those with MRSA, prompting further exploration of a second Phase III study[16] - AR-301's global Phase III study did not achieve its primary endpoint, yet showed promising trends in older patients and those with antibiotic-resistant infections, leading to discussions with FDA and EMA for a new study design[17] - RVX-208 has completed Phase III trials and received breakthrough therapy designation from the FDA, aiming to reduce major adverse cardiovascular events in high-risk patients[18] - H1710, an acetyl heparinase inhibitor, is in preclinical stages and has shown significant anti-tumor effects in various models, with IND applications planned for China and the US[19] Governance and Compliance - The board of directors includes four executive directors and three independent non-executive directors, ensuring that independent opinions are represented[79] - The audit committee has reviewed the consolidated annual performance for the year ending December 31, 2023, and confirmed compliance with relevant accounting standards and regulations[84] - Ernst & Young confirmed that the financial figures in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2023[85]

重大投资决策管理制度 深圳市海普瑞药业集团股份有限公司 重大投资决策管理制度 第一章 总 则 第一条 为规范深圳市海普瑞药业集团股份有限公司（以下简称"公司"） 的投资管理，提高公司对内及对外投资决策的合理性和科学性，规避投资风险， 强化决策责任，实现公司资产保值增值及股东利益最大化的目标，现依据《中华 人民共和国公司法》（以下简称"《公司法》"）、《深圳证券交易所股票上市规 则》（以下简称"《深交所上市规则》"）、《香港联合交易所有限公司证券上市 规则》（以下简称"《香港上市规则》"），"香港联合交易所有限公司"以下简称 "香港联交所"）及《深圳市海普瑞药业集团股份有限公司章程》（以下简称"《公 司章程》"）等有关规定，结合公司的实际情况，制定本制度。 第二条 公司投资必须遵循"规范、合理、科学、优质、高效"的原则，符合 国家的产业政策，符合公司的经营发展战略。 第三条 公司实行股东大会、董事会、董事长分层决策制度，下属分公司无 权决策对外投资，子公司在公司授权范围内进行投资决策。 第四条 股东大会、董事会、监事会、相关职能部门及公司的高级管理人员 均应严格遵守《公司法》及其他法律、行政法规、规范性文件、公 ...

证券代码：002399 证券简称：海普瑞 公告编号：2023-041 深圳市海普瑞药业集团股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市海普瑞药业集团股份有限公司（以下简称"公司"）第六届董事会第 五次会议（以下简称"会议"）通知及议案于2023年11月14日以电子邮件的形式 发出，会议于2023年11月20日下午14:00以通讯方式召开。本次会议应参与表决 董事7人，实际以通讯方式参与表决董事7人。公司监事及高级管理人员列席会议， 会议由公司董事长李锂先生主持。本次会议的通知、召开以及参与表决董事人数 均符合相关法律法规及《公司章程》的有关规定。 经与会董事认真审议通过了以下议案： 一、《关于修订<公司章程>及相关制度的议案》 表决结果：7票同意、0票弃权、0票反对。本议案尚需提交公司股东大会、 类别股东会议以特别决议审议批准。 公司《关于修订公司治理相关制度的公告》刊登于信息披露媒体：《证券时 报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网www.cninfo.com.cn。 三、《关于 ...

深圳市海普瑞药业集团股份有限公司 《公司章程》修订对照表（2023 年 11 月） 深圳市海普瑞药业集团股份有限（以下简称"公司"）于 2023 年 11 月 20 日 召开第六届董事会第五次会议，审议通过了《《关于修订<公司章程>及公司部分内 部管理制度的议案》，拟对《公司章程》进行相应的修改，本次章程修订对照表 如下： | 原《公司章程》内容 | 修订后《公司章程》内容 | | --- | --- | | 第一章 总则 | 第一章 总则 | | 第一条 为维护公司、股东和债权人的合法 | 第一条 为维护公司、股东和债权人的合法 | | 权益，规范公司的组织和行为，根据《《中华 | 权益，规范公司的组织和行为，根据《《中华 | | 人民共和国公司法》（以下简称"《《公司 | 人民共和国公司法》（以下简称"《公司 | | 法》"）、《中华人民共和国证券法》（以下简 | 法》"）、《中华人民共和国证券法》（以下简 | | 称"《《证券法》"）、《国务院关于股份有限公 | 称"《《证券法》"）、《境内企业境外发行证券 | | 司境外募集股份及上市的特别规定》（以下 | 和上市管理试行办法》、《上市公司章程指 | ...

证券代码：002399 证券简称：海普瑞 公告编号： 2023-046 深圳市海普瑞药业集团股份有限公司 关于召开2023年第一次临时股东大会、2023年第一次A股类 别股东会议及第一次H股类别股东会议的通知公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据深圳市海普瑞药业集团股份有限公司（以下简称"公司"）于2023年11 月20日召开的第六届董事会第五次会议决议的内容，公司定于2023年12月15日召 开2023年第一次临时股东大会、2023年第一次A股类别股东会议及第一次H股类 别股东会议（以下简称"本次股东大会"），现将相关事项公告如下： 一、召开会议的基本情况 1、股东大会届次：2023年第一次临时股东大会、2023年第一次A股类别股 东会议及第一次H股类别股东会议 2、股东大会的召集人：第六届董事会 6、股权登记日及出席对象： 3、会议召开的合法、合规性：本次会议审议的议案经第六届董事会第五次 会议、第六届监事会第四次会议通过后提交，程序符合有关法律、行政法规、部 门章程、规范性文件和公司章程的规定。 4、会议召开的日期、时间： 现场会议时 ...

关联交易决策制度 深圳市海普瑞药业集团股份有限公司 关联交易决策制度 第一章 总则 第一条 为维护深圳市海普瑞药业集团股份有限公司（以下简称"公司"）及 全体股东的利益，规范关联交易，根据《中华人民共和国公司法》、《深圳证券交 易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第1号——主板上 市公司规范运作》、《香港联合交易所有限公司证券上市规则》（以下简称"《香港 上市规则》"，"香港联合交易所有限公司"以下简称"香港联交所"）及其他相关法 律、法规规定和《深圳市海普瑞药业集团股份有限公司章程》（以下简称"《公司 章程》"），制定本制度。 第二条 上市公司关联交易应当遵循的原则： （一）符合诚实信用； 第四条 公司的关联交易，是指公司或公司控股子公司与公司关联人之间发 生的转移资源或义务的事项，包括： （一）购买或出售资产； （二）对外投资（含委托理财、对子公司投资等）； 1 关联交易决策制度 （三）提供财务资助（含委托贷款等）； （二）符合公平、公开、平等、自愿的原则； （三）遵循市场定价原则，关联交易的价格应不偏离市场独立第三方的价格 或收费的标准。 第三条 关联交易在提交审批机构审批之前，交易 ...

会计师事务所选聘制度 深圳市海普瑞药业集团股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为规范深圳市海普瑞药业集团股份有限公司（以下简称"公司"） 选聘（含续聘、改聘）会计师事务所的行为，切实维护股东利益，提高财务信息 质量，根据证券监督管理部门的相关要求，制定本制度。 第二条 公司选聘（含续聘、改聘）进行会计报表审计等业务的会计师事务 所（以下简称"会计师事务所"），需遵照本制度的规定。 第三条 公司选聘会计师事务所应经董事会审计委员会（以下简称"审计委 员会"）审议同意后，提交董事会审议，并由股东大会决定。公司不得在董事 会、股东大会审议前聘请会计师事务所开展审计业务。 第二章 会计师事务所执业质量要求 第四条 公司选聘的会计师事务所应当具有证券期货相关业务资格，具有良 好的执业质量记录，并满足下列条件： （一）具有独立的法人资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； （三）熟悉国家有关财务会计方面的法律、法规、规章和政策； （四）具有完成审计任务和确保审计质量的注册会计师； （五）认真执行有关财务审计的法律、法规、规章和政策规定，具有良好的 社会声誉和执业质 ...

深圳市海普瑞药业集团股份有限公司 董事、监事和高级管理人员薪酬与绩效考核制度 第一章 总 则 第一条 为建立与现代企业制度相适应的收入分配制度，吸引优秀的管理人 才，建立和完善经营者的激励约束机制，保持核心管理团队的稳定性，有效地调 动董事、监事和高级管理人员的积极性和创造性，提高企业经营管理水平，将经 营者的利益与企业的长期利益结合，促进企业健康、持续、稳定发展，根据《中 华人民共和国公司法》等有关法律及《深圳市海普瑞药业集团股份有限公司章程》 （以下简称"《公司章程》"），公司董事会特制定《董事、监事和高级管理人员薪 酬与绩效考核制度》(以下简称"本制度")。 第二条 适用本制度的董事、监事、高级管理人员包括： （七）以《公司章程》规定或经公司董事会薪酬与考核委员会(以下简称"薪 酬与考核委员会")认定的其他人员。 第三条 公司兼任管理职务的董事、高级管理人员（以下简称"相关管理人 员"）的薪酬分配与考核以企业经济效益为出发点，根据公司年度经营计划和相 关管理人员分管工作的工作目标，进行综合考核，根据考核结果确定相关管理人 员的薪酬。 未兼任管理职务的董事不在公司领取薪酬；独立董事根据股东大会批准的独 立 ...

证券代码：002399 证券简称：海普瑞 公告编号：2023-044 深圳市海普瑞药业集团股份有限公司 公司自 2020 年 H 股上市至今，制剂业务发展向好， 2020 年、2021 年、2022 年制剂业务销售收入分别为人民币 1,510.7 百万元、人民币 2,638.2 百万元、人民 币 3,210.5 百万元，其过去三年的复合增长率为 37.7%。公司认为应按招股章程 中的所得款项用途，进一步增加资源用作支持在欧盟及其他全球市场（如中国） 拓展销售及营销网络以及基础设施，使得公司可以更好地拓展运营以支持销售扩 张，包括及不限于提升生产能力、扩大生产规模、增加生产资源采购及储备，更 全面地调研目标市场，更有的放矢地开拓市场，持续推动业务增长。公司认为进 一步重新分配未动用所得款项将更有利于公司未来的业务增长，并提高公司的盈 利能力。 | 单位：人民币百万元 | | --- | | 序 | 项目名称 | 变更前 募集资 | 已使用 | | 变更后 募集资 | 已使用 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | | | | 募集资 ...